» Articles » PMID: 11437097

Oncostatin M-induced Growth Inhibition and Morphological Changes of MDA-MB231 Breast Cancer Cells Are Abolished by Blocking the MEK/ERK Signaling Pathway

Overview
Specialty Oncology
Date 2001 Jul 5
PMID 11437097
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Cytokine oncostatin M (OM) has profound effects on proliferation and differentiation of breast cancer cells. OM treated cells show reduced growth rate and differentiated phenotypes. The mechanisms underlying the OM growth-inhibitory activity in breast cancer cells have not been fully elucidated. In this study, we investigated the OM-elicited signaling pathways in breast cancer cell lines MDA-MB231 and MCF-7. We show that OM rapidly activates the extracellular signal-regulated kinase (ERK) and the signal transducer and activator of transcription (STAT) 1 and 3 in both cell lines. Intriguingly, OM-induced growth inhibition and morphological changes in MDA-MB231 cells are completely abolished by inhibitors to ERK upstream kinase MEK (nitrogen/extracellular-regulated protein kinase kinase), but the MEK inhibitors have little effects on OM growth-inhibitory activity in MCF-7 cells. In addition, expressions of the cyclin kinase inhibitors p21 and p27 are strongly induced by OM in MCF-7 cells, but their expression is only slightly increased by OM in MDA-MB231 cells. These data together demonstrate that the growth-inhibitory activity of OM can be mediated by different signaling pathways in a cell line-specific manner. While the MEK/ERK pathway is the predominant signaling pathway that leads to the growth inhibition of MDA-MB231 cells, activation of additional signaling pathways are necessary for OM to exert its growth-inhibitory activity in MCF-7 cells.

Citing Articles

A combination of myokines and genistein suppresses cancer stemness in MCF-7 human breast cancer cells.

Kwon H, Kim Y, Kim J Nutr Res Pract. 2024; 18(3):436-445.

PMID: 38854472 PMC: 11156767. DOI: 10.4162/nrp.2024.18.3.436.


Exercise Suppresses Head and Neck Squamous Cell Carcinoma Growth via Oncostatin M.

Yoshimura T, Hirano Y, Hamada T, Yokoyama S, Suzuki H, Takayama H Cancers (Basel). 2024; 16(6).

PMID: 38539521 PMC: 10969669. DOI: 10.3390/cancers16061187.


The clinical relevance of OSM in inflammatory diseases: a comprehensive review.

Wolf C, Pruett C, Lighter D, Jorcyk C Front Immunol. 2023; 14:1239732.

PMID: 37841259 PMC: 10570509. DOI: 10.3389/fimmu.2023.1239732.


Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer.

Caligiuri A, Gitto S, Lori G, Marra F, Parola M, Cannito S Cancers (Basel). 2022; 14(17).

PMID: 36077744 PMC: 9454586. DOI: 10.3390/cancers14174211.


The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer.

Martinez-Perez C, Kay C, Meehan J, Gray M, Dixon J, Turnbull A J Pers Med. 2021; 11(11).

PMID: 34834425 PMC: 8624266. DOI: 10.3390/jpm11111073.